subject area of
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum Academic Article
- Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes ( REWIND ) trial on the cardiovascular effects of dulaglutide Academic Article
- Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes Academic Article
- Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus Academic Article
- GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R Academic Article
- Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies Academic Article
- Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation Academic Article
- Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study Academic Article
- Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies Academic Article
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome Academic Article
- The Triumph of Innovation and the Hard Work of Caring for Patients With Diabetes Academic Article